William Blair initiates coverage on Acer Therapeutics (NASDAQ: ACER) with an Outperform rating and fair value target of $47.Analyst Tim ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE